[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"American University of Beirut Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":529},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,42,68,93,120,151,177,200,224,246,279,301,325,351,371,396,421,445,468,496],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100583472","effect-of-pediatric-lung-ultrasound-on-antibiotic-prescriptions-in-hospitalized-children-and-adolescents-with-lower-respiratory-tract-infections-a-randomized-controlled-trial-100583472",false,"NCT06876766","Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents With Lower Respiratory Tract Infections. A Randomized Controlled Trial.","Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents With Lower Respiratory Tract Infections.","PLUS-AP","Inclusion Criteria:\n\n* Age between 3 months and 17 years old inclusive\n* Currently admitted to the pediatric Ward or boarding in the Emergency Department within 24 hours of admission order due to lower respiratory tract infections.\n\nExclusion Criteria:\n\n* Sickle cell disease (SCD).\n* On chemotherapy or any other immunosuppressive therapy except systemic corticosteroids use of ≤ 5 days duration.\n* Cystic fibrosis and other chronic lung diseases except asthma\n* Pre-existing and\u002For congenital neurologic, metabolic, and cardiac conditions\n* Hospitalized within the previous month\n* Patients with suspected foreign body aspiration -Received antibiotic therapy within the previous week\n* Patients admitted under PI's care","ALL","3 Months","18 Years",{"count":21,"type":22},176,"ESTIMATED","INTERVENTIONAL",[25],"NA","Title: Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents with Lower Respiratory Tract Infections (PLUS-AP Trial)\n\nPurpose of the Study:\n\nThis study is being done to find out if a type of imaging called lung ultrasound (LUS) can help doctors decide when to stop antibiotics in children and teens who are in the hospital with lung infections, like pneumonia. Antibiotics are often given to these patients, but sometimes they are used for longer than necessary, which can be harmful. The investigators want to see if using LUS helps doctors make decisions that reduce unnecessary antibiotic use, which can help prevent antibiotic resistance and other complications.\n\nWhat is Lung Ultrasound (LUS)? Lung ultrasound is a safe, non-invasive, and painless test that uses sound waves to look at the lungs. It doesn't involve radiation like chest X-rays. It is already being used to help doctors understand lung conditions, and this study will test if it can also help in deciding when to stop antibiotics.\n\nHow the Study Works:\n\nParticipants: Children and adolescents (ages 3 months-18 years) who are admitted to the hospital with a lung infection.\n\nGroups:\n\nLUS Group: These patients will have a lung ultrasound within 24 hours of enrollment. The results will help guide decisions about when to stop antibiotics.\n\nStandard Care Group: These patients will receive regular hospital care, which may include chest X-rays and other tests to guide their treatment.\n\nWhat Will Be Measured?\n\nPrimary Goal: The study will measure how long children and teens stay on antibiotics. The investigators are testing whether LUS can help shorten this time without affecting their recovery.\n\nSecondary Goals: Investigators will also look at how long patients stay in the hospital, whether they need further treatment or care after leaving.\n\nWhy is This Important? If this study shows that LUS can safely reduce the use of antibiotics, it could change how doctors treat lung infections in children. Reducing unnecessary antibiotic use can help fight antibiotic resistance and protect children from side effects of unnecessary treatments.",[28],"Lower Resp Tract Infection","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2025-04-02",{"date":37,"type":22},"2027-06",{"name":39,"class":40},"American University of Beirut Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100636109","erector-spinae-block-versus-paravertebral-block-on-chronic-pain-after-mastectomy-100636109","NCT07561411","Erector Spinae Block Versus Paravertebral Block on Chronic Pain After Mastectomy","The Effect of Erector Spinae Block Versus Paravertebral Block on the Incidence of Chronic Pain After Mastectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients between 18 and 80 years old.\n* Scheduled to total mastectomy with or without axillary dissection\n* Willing to receive regional anesthesia in addition to GA\n* ASA classification 1-3\n\nExclusion Criteria:\n\n* Previous thoracic surgery with an incision of \\>2 cm\n* Patient's refusal\n* Allergy to local anesthetics\n* Pregnant women\n* Any contraindications to thoracic PVB, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy; anticoagulants intake.\n* American Society of Anesthesiologists (ASA) classification of 4 or higher,\n* History of chronic pain or untreated clinical severe depression",true,"80 Years",{"count":52,"type":22},132,[25],"The goal of this clinical trial is to learn if the erector spinae block can reduce the incidence of chronic pain compared to the paravertebral block in adult patients undergoing total mastectomy. The study includes patients aged 18 to 80 years scheduled for mastectomy, with or without axillary dissection. The main questions it aims to answer are:\n\n* Does erector spinae block reduce the incidence of chronic pain at 3 months after mastectomy compared to paravertebral block?\n* Does erector spinae block affect postoperative outcomes such as opioid consumption at 48 hours, pain scores (in PACU, 24 and 48 hours), block performance time, and the incidence of complications, anxiety or depression, and pain intensity at 3 months?\n\nResearchers will compare patients receiving erector spinae block to those receiving paravertebral block to determine if erector spinae block provides equivalent or improved outcomes in terms of chronic pain and perioperative measures.\n\nParticipants will:\n\n* Be randomly assigned to receive either erector spinae block or paravertebral block prior to surgery\n* Undergo total mastectomy (with or without axillary dissection)\n* Have their pain assessed in the PACU and at 24 and 48 hours postoperatively\n* Have opioid consumption measured during the first 48 hours after surgery\n* Be followed up at 3 months to assess chronic pain, pain intensity, and psychological outcomes (anxiety or depression)",[56,57,58,59],"Mastectomy; Lymphedema","Chronic Pain","Regional Anesthesia Morbidity","Opioid Use","2026-06-01",{"date":62,"type":33},"2026-06-02",{"date":64,"type":33},"2026-05-19",{"date":66,"type":22},"2028-05-01",{"name":39,"class":40},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":41},"100601477","testing-the-epley-maneuver-for-treating-dizziness-in-the-emergency-department-100601477","NCT07111000","Testing the Epley Maneuver for Treating Dizziness in the Emergency Department","Evaluating the Efficacy of Epley Maneuver in the Treatment of Benign Paroxysmal Positional Vertigo in the Emergency Department: A Randomized Controlled Trial.","Inclusion Criteria\n\n* Age: above 18 years old\n* Patients presenting to the ED with symptoms of BPPV (single or recurrent episodes of vertigo lasting up to 2 minutes) and a positive DHT (episode of vertigo associated with torsional upbeating nystagmus) indicating a posterior semicircular canal BPPV.\n* Patients who are able to understand and provide a signed informed consent to participate in the study Exclusion Criteria\n* Severe cervical diseases (e.g., soft tissue disorders, cervical spondylosis, prolapsed intervertebral disks and severe rheumatoid arthritis with cervical instability …)\n* Unstable cardiovascular diseases (e.g., hemodynamically unstable, decompensated heart failure, acute myocardial infarction, decompensated valvular diseases, severe arrhythmias …)\n* Suspected vertebrobasilar diseases (e.g., cerebellar signs, vision changes, numbness or tingling in the extremities, slurred speech, changes in mental status, confusion …)\n* History of high-grade carotid stenosis\n* Recent (\\\u003C24 hours) intake of aminoglycosides, chemotherapeutic agents, cyclophosphamide, loop diuretics, or quinines\n* Patients with peripheral causes of vertigo other than BPPV (such as Meniere's disease or vestibular neuritis)\n* Patients with central causes of vertigo (vestibular migraine, Arnold Chiari malformation, history of CNS tumor(s), multiple sclerosis)\n* Patients with focal deficits on neurological exam\n* Patients with an episode of vertigo lasting more than 2 minutes\n* Patients with a negative DHT\n* Patients with pure horizontal or vertical nystagmus\n* Patients with lateral and anterior semicircular canals BPPV\n* Participants refusing to undergo Epley maneuver\n* Pregnancy beyond the 24th week of gestation",{"count":76,"type":22},118,[25],"The goal of this randomized controlled trial is to evaluate the efficacy of the Epley maneuver versus a sham maneuver in treating patients presenting to the emergency department (ED) with BPPV. The main questions that the study aims to answer are:\n\n* What is the mean difference in Dizziness Handicap Inventory (DHI) scores between patients receiving the Epley maneuver and those receiving the sham maneuver 3 days after enrollment?\n* What is the immediate response (using a 0-10-point Likert scale) of patients in each arm of the study?\n* What is the proportion of patients who, despite agreeing to participate, were unable to complete the full Epley maneuver due to symptom severity?\n\nResearchers will compare the Epley maneuver arm to the sham maneuver arm to see if the Epley maneuver is more effective in reducing BPPV symptoms.\n\nParticipants will:\n\n* Undergo either the Epley maneuver or a sham maneuver.\n* Complete the Dizziness Handicap Inventory (DHI) questionnaire at baseline and 3 days post-discharge.\n* Patients with insufficient improvement in the sham maneuver group will receive a rescue Epley maneuver.\n* Have their vertigo severity assessed using a 0-10 point Likert scale at baseline, immediately and post-maneuver.",[80],"Benign Paroxysmal Positional Vertigo (BPPV)",[82,83,84],"Epley","vertigo","bening paroxysmal positional vertigo","2026-05-06",{"date":87,"type":33},"2026-05-11",{"date":89,"type":33},"2024-08-01",{"date":91,"type":22},"2026-08-22",{"name":39,"class":40},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":49,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100629964","impact-of-intermittent-fasting-on-the-mental-health-of-perimenopausal-women-100629964","NCT07481513","Impact of Intermittent Fasting on the Mental Health of Perimenopausal Women","Inclusion Criteria:\n\n* Participants eligible in this study will be women between the ages of 45 and 55 who are in the perimenopausal stage as defined by the STRAW criteria and confirmed using the Menopausal Rating Scale (MRS).\n\nExclusion Criteria:\n\n* Currently using hormone replacement therapy\n* Diagnosed with severe medical conditions that could interfere with fasting, including uncontrolled diabetes, heart disease, hypertension, cancer or kidney disease\n* Have a current formal mental health diagnosis as defined by the DSM-5, regardless of whether they are receiving medication or therapy\n* Experiencing any form of dementia\n* Have undergone surgical menopause, have premature ovarian failure, are currently undergoing chemotherapy or radiotherapy, or are ovarian cancer survivors\n* Are currently pregnant. undergoing treatment for endometriosis, have significant thyroid disorders, or are on any form of hormone therapy\n* Do not speak English\n* Participants who score greater than 0 on question 9 of the PHQ-9 (including suicidal ideation) will be removed from the trial and provided with mental health referrals to NGOs for support.","FEMALE","45 Years","55 Years",{"count":103,"type":22},140,[25],"This study will explore how intermittent fasting (specifically the 16\u002F8 method) affects the mental health of women who are in the perimenopause stage. This life stage often brings hormonal changes that can impact emotional and physical well-being. The study will include 98 women aged 45-55, who will be randomly divided into two groups. The study will compare the mental health outcomes of those who follow intermittent fasting with those who do not, using independent t-tests to analyze the results. The goal is to better understand if intermittent fasting can help improve mental health during perimenopause.",[107,108,109],"Mental Health","Perimenopause","Intermittent Fasting",[109,107,108,111],"Depression","2026-03-16",{"date":114,"type":33},"2026-03-19",{"date":116,"type":33},"2025-09-23",{"date":118,"type":22},"2026-12",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100622763","phase-2-glofitamab-as-a-bridge-to-andor-consolidation-post-autologous-stem-cell-transplant-in-patients-with-relapsed-b-cell-lymphomas-100622763","NCT07387848","Glofitamab as a Bridge to and\u002For Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas","A Phase II,Open Label, Single Arm, Multicenter Study Investigating the Efficacy and Safety of Glofitamab When Used as a Bridge to and\u002For Consolidation Post-transplant for Patients With Relapsed\u002FRefractory B-cell Lymphomas Transformed Low Grade B Cell Lymphoma) Fit and Eligible for ASCT","GLO-PACT","Inclusion Criteria:\n\n\\- To be eligible to participate in this trial, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form (ICF) ) by the patient\u002Fimpartial witness\u002Flegal representative before any trial related procedures.\n2. Male or female aged between 18 and 65 years.\n3. Ability and willingness to comply with the study protocol.\n4. Histologically confirmed diagnosis of primary refractory or relapsed DLBCL (all subtypes including primary mediastinal B cell lymphoma, high grade B cell lymphoma, large B cell lymphoma etc) or transformed low grade B cell lymphoma planned for salvage Rituximab-chemotherapy regimens followed by ASCT.\n5. Patients with a life expectancy of at least 6 months.\n6. All patients must be stable without any signs of active infection, systemic (oral or parenteral) corticosteroid or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated.\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks.\n8. Women of child-bearing potential and male subjects shall agree to take medically acceptable contraception measures while on study treatment and for 3 months following completion of study treatment. All women of child-bearing potential must have a negative blood pregnancy test at screening.\n\n   Women must remain abstinent or use contraceptive methods with a failure rate of ≤1% per year during the study treatment period and for 2 months after the final dose of glofitamab, 3 months after the final dose of tocilizumab (if applicable), 12 months after rituximab or chemotherapy, or 18 months after the final dose of obinutuzumab. Women must refrain from donating eggs during this same period. A woman is considered of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the investigator (i.e., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations. Examples of contraceptive methods with a failure rate of ≤1% per year include bilateral tubal ligation, male sterilization, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post ovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form. For men who are not surgically sterile (or with azoospermia for other reasons): Investigators will discuss sperm conservation prior to initiation of study treatment for male participants. Participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating sperm, as defined below: With a female partner of childbearing potential who is not pregnant, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of ≤1% per year during the study treatment period and for 2 months after the final dose of glofitamab, 3 months after the final dose of tocilizumab (if applicable), 6 months after rituximab, ICE (ifosfamide, carboplatin, and etoposide) or obinutuzumab. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post ovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n9. Patients with at least one bi-dimensionally measurable (≥1.5 cm) nodal lesion, or one bi-dimensionally measurable (≥1 cm) extranodal lesion, as measured on CT scan.\n10. Adequate hematologic function (unless attributable to the underlying disease, as established by extensive bone marrow involvement or associated with hypersplenism secondary to the involvement of the spleen by DLBCL per the investigator), defined as follows:\n\n    \\- ANC ≥1.0 x109\u002FL ( ≥1000\u002FμL) Participants with a history of benign ethnic neutropenia may be included with ANC ≥0.75x109\u002FL (≥750\u002FμL).\n\n    \\- Platelet count ≥50x109\u002FL (≥50,000\u002FμL) without a transfusion in the week prior to starting study treatment.\n11. Adequate renal function, defined as an estimated CrCl ≥ 45 mL\u002Fmin.\n12. Participants who have a negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count ≥200\u002FμL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months.\n\nExclusion Criteria:\n\n* An individual, who meets ANY of the following criteria, will be excluded from participation in this trial:\n\n  1. Patients receiving any investigational drug, biological, immunological therapy within the previous 21 days before enrollment.\n  2. Presence of any severe or uncontrolled systemic disease or condition, including serious cardiac, pulmonary or renal conditions; any type of bacterial, viral, fungal or other infection that would pose a significant risk to the patient in the opinion of the investigator; or active Hepatitis B or positive HCV antibodies.\n  3. Any unresolved toxicities from prior therapy, greater than CTCAE-version 5 grade 2 at the time of starting study treatment, with exception of alopecia.\n  4. Patients with a significant cardiovascular disease or condition, including any of the following:\n\n     1. Congestive heart failure (CHF) currently requiring therapy and patients with New York Heart Association Class III\u002FIV CHF\n     2. LVEF \\\u003C 50%\n     3. Need for antiarrhythmic medical therapy for a ventricular arrhythmia or patients with uncontrolled or unstable cardiac arrhythmias\n     4. Severe conduction disturbance (e.g., second- or third-degree AV block)\n  5. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n     1. Absolute neutrophil count \\\u003C 1 x 109\u002FL (or \\\u003C 0.75 x 109\u002FL in case of ethnic neutropenia due to excess margination)\n     2. Platelet count \\\u003C 50 x 109\u002FL (Transfusion-dependent patients are excluded)\n  6. Severe hepatic and\u002For renal impairment as demonstrated by any of the following:\n\n     a. Alanine aminotransferase \\> 2.5 times the upper limit of normal (ULN) b. Aspartate aminotransferase \\> 2.5 times ULN c. Total bilirubin \\> 1.5 times ULN (Total bilirubin \\>3 times the ULN in patients with documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) d. Creatinine clearance \\\u003C 45 mL\u002Fmin (measured or calculated by Cockcroft and Gault equation). Confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN\n  7. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with all study procedures and treatment.\n  8. Significant medical or psychiatric illness that would interfere with compliance and ability to tolerate treatment as outlined in the protocol.\n  9. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products.\n  10. The presence of any contraindication to: Obinutuzumab, rituximab, or tocilizumab.\n  11. Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3.\n\n  10\\. Peripheral neuropathy assessed to be Grade \\>1 according to National Cancer Institute (NCI) CTCAE) v5.0 at Enrollment.\n\n  11\\. Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, o neurodegenerative disease (note: Participants with a history of stroke who have not experienced a stroke or transient ischemic attack within the past 2 years and have no residual neurologic deficits, as judged by the investigator, are allowed).\n\n  12\\. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 2 weeks prior to the first study treatment. 13. History of other malignancy that could affect compliance with the protocol or interpretation of results, with the following exceptions:\n\nNote:\n\n* Participants with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix at any time prior to enrollment are allowed.\n* Participants with low-grade, early-stage prostate cancer (Gleason score 6 or below, Stage 1 or 2 with no requirement for therapy at any time prior to enrollment are allowed.\n* Participants with any other malignancy appropriately treated with curative intent and the malignancy has been in remission without treatment for ≥ 2 years prior to enrollment are eligible.\n* Participants receiving adjuvant endocrine therapy for non-metastatic, hormone receptor positive breast cancer for ≥2 years prior to enrollment are eligible.\n\n  14\\. Contraindications to treatment with rituximab, Obinutuzumab or tocilizumab.","65 Years",{"count":130,"type":22},40,[132],"PHASE2","This is an investigator-initiated, open-label, single-arm, multicenter, Phase II clinical study. The study is designed to evaluate the safety and potential effectiveness of glofitamab in adults with their disease, diffuse large B-cell lymphoma (DLBCL has either not responded to initial treatment or has returned after an initial response and who are eligible and medically fit for autologous stem cell transplantation (ASCT). Autologous stem cell transplantation is a commonly used treatment in this situation and involves high-dose chemotherapy followed by infusion of your own stem cells, which are collected from your blood several weeks before the transplant.\n\nThe purpose of this study is to assess glofitamab, which is not part of standard treatment. Glofitamab is a type of antibody designed to attach to both lymphoma cells and certain immune cells called T cells. By bringing these cells together, glofitamab may help activate the immune system so that T cells can better recognize and destroy lymphoma cells. In this study, glofitamab may be used as a \"bridge\" to transplantation and\u002For as consolidation treatment after the transplant, depending on how the disease responds to chemotherapy given before the transplant.\n\nIn recent years, newer immune-based treatments such as CAR-T cell therapy have shown benefit for patients whose lymphoma does not respond to or returns after chemotherapy. CAR-T therapy involves collecting immune cells, modifying them in a laboratory, and then reinfusing them into the patient. However, access to CAR-T therapy is limited in some regions, including Lebanon, and autologous stem cell transplantation remains an important treatment option",[135],"Diffuse Large B Cell Lymphoma Refractory",[137,138,139,140,141],"Glofitamab","DLBCL","Relapse","Refractory","ASCT","NOT_YET_RECRUITING","2026-01-30",{"date":145,"type":33},"2026-02-04",{"date":147,"type":22},"2026-04-15",{"date":149,"type":22},"2031-12-15",{"name":39,"class":40},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":99,"minAge":19,"maxAge":50,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":41},"100509419","phase-2-vitamin-c-effectiveness-in-preventing-urinary-tract-infections-after-gynecological-surgeries-100509419","NCT05913180","Vitamin C Effectiveness in Preventing Urinary Tract Infections After Gynecological Surgeries","Vitamin C for the Prevention of Catheter-associated Urinary Tract Infections in Women Who Undergo Elective Gynecological Surgeries: a Randomized Double-blinded Controlled Trial","Inclusion Criteria:\n\n* Nonpregnant women\n* 18 years of age or older\n* Undergoing elective GYN surgery\n\nExclusion Criteria:\n\n* Pregnant women\n* Already taking Vitamin C supplementation\n* Nephrolithiasis\n* Congenital anomaly or neurogenic bladder\n* Allergy to ascorbic acid\n* On therapeutic anticoagulant medicine during the 6 weeks after surgery\n* Gynecological surgery involving fistula repair or a vaginal mesh removal\n* Positive Urinalysis in the pre-admission unit\n* Recurrent UTIs\n* Diabetes\n* G6PD\n* Hemochromatosis\n* Renal disorders",{"count":159,"type":22},180,[132],"Double-blind placebo-controlled randomized trial aiming to assess the role of Vitamin C supplementation in the prevention of catheter-associated urinary tract infections in women undergoing elective gynecological surgeries.",[163],"Catheter-Associated Urinary Tract Infection",[165,166,167,168],"Ascorbic acid","Vitamin C","Elective Gynecologic surgeries","CAUTI","2025-12-23",{"date":171,"type":33},"2025-12-30",{"date":173,"type":33},"2023-09-19",{"date":175,"type":22},"2026-08-15",{"name":39,"class":40},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":49,"sex":17,"minAge":19,"maxAge":101,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":41},"100553584","asleep-fiberoptic-vs-direct-laryngoscopy-effect-on-hemodynamic-stability-using-opioid-free-anesthesia-induction-100553584","NCT06487988","Asleep Fiberoptic vs Direct Laryngoscopy Effect on Hemodynamic Stability Using Opioid Free Anesthesia Induction","Inclusion Criteria:\n\n* ASA (American Society of Anesthesiologists) physical status I and II\n* Range age of 18-55 years' old\n* Scheduled for elective surgery under general anesthesia.\n\nExclusion Criteria:\n\n* History of cardiovascular diseases.\n* History of lung disease.\n* Hypertensive patient (BP\\> 140\u002F90)\n* Patient taking medications that affect blood pressure and heart rate\n* Morbid obesity (BMI \\>30)\n* Severe GERD\n* Predicted difficult airway (Short TMD \\\u003C6 cm, Upper li bite test grade III, Mallampati score\n\n  \\>III)\n* Neck instability\n* Patient planned to receive rapid sequence intubation\n* Patient refusal to participate\n* History of difficult intubation\u002F ventilation",{"count":184,"type":22},90,[25],"The goal of this clinical trial is to compare blood pressure and heart rate between the fiberoptic and direct oral intubation using opioid free anesthesia induction. Secondary objectives include comparing the time needed for intubation and the incidence of postoperative sore throat, hoarseness, and upper airway trauma in adults aging between 18 to 55 years, scheduled for elective surgery under general anesthesia.\n\nThe main question it aims to answer is:\n\nDoes fiberoptic intubation cause less hemodynamic instability than direct oral intubation using opioid free anesthesia induction?",[188,189,190,191],"Analgesics, Opioid","Anesthesia, General","Heart Rate","Blood Pressure","2025-12-15",{"date":194,"type":33},"2025-12-19",{"date":196,"type":33},"2024-09-11",{"date":198,"type":22},"2026-01-01",{"name":39,"class":40},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":49,"sex":17,"minAge":4,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":41},"100597525","femoral-arterial-cannulation-in-pediatrics-100597525","NCT07059624","Femoral Arterial Cannulation in Pediatrics","Femoral Arterial Cannulation Performed by Anesthesia Residents: A Comparison Between Ultrasound-Guided \"Modified Dynamic Needle Tip Positioning, Short-Axis, Out-Of-Plane\" and \"Conventional, Short-Axis, Out-Of-Plane\" Methods","Inclusion Criteria:\n\n* Infants and children under 12 years of age.\n* American Society of Anesthesiologist (ASA) physical status II-IV.\n* Patients with congenital heart disease undergoing cardiac surgery who do not have existing arterial line access.\n\nExclusion Criteria:\n\n* Need for emergency surgery.\n* Hemodynamic instability.","12 Years",{"count":209,"type":22},80,[25],"The goal of this clinical trial\\] is to evaluate the efficacy and safety of the ultrasound-guided \"Modified Dynamic\n\nNeedle Tip Positioning Short-Axis, Out-Of-Plane\" (MDNTP-SAOP) technique compared to the \"Conventional, Short-Axis, Out-Of-Plane\" (C-SAOP) technique for femoral arterial cannulation performed by anesthesia residents in children. The main question it aims to answer is:\n\nWhat is the time required for attempted femoral arterial cannulation by anesthesia residents at the first puncture site?\n\nResearchers will compare the efficacy and safety of MDNTP-SAOP versus C-SAOP methods for femoral arterial cannulation performed by anesthesia residents in infants and children undergoing cardiac surgery.\n\nParticipants will be randomized to either the MDNTP-SAOP or the C-SAOP group. Intraoperatively, time taken for attempted cannulation by the resident at the first site of femoral arterial puncture, number of attempts at arterial cannulation, and number of cannulae required for successful cannula insertion will be recorded. Adverse events will be monitored on postoperative days 1 and 3. The insertion site will be examined for thrombosis, hematoma, infection, or limb ischemia distal to the insertion site",[213,214,215],"Pediatric ALL","Cardiac Complication","Anesthesia","2025-07-18",{"date":218,"type":33},"2025-07-20",{"date":220,"type":33},"2025-07-09",{"date":222,"type":22},"2027-01-01",{"name":39,"class":40},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100594736","ball-exercises-to-prevent-frailty-in-older-adults-leopard-100594736","NCT07023328","BalL Exercises tO Prevent FrAilty in OldeR ADults (LEOPARD)","BalL Exercises tO Prevent FrAilty in OldeR ADults (LEOPARD): A Pragmatic, Open-label, Randomized Controlled Trial.","(LEOPARD)","Inclusion Criteria\n\n* Age between 65 and 75 years\n* Pre-frail status according to the FRAIL Scale assessment\n* Ability to rise from a chair without assistance\n* Ability to perform the Apley scratch test\n* Ability to bend forward without significant pain\n\nExclusion Criteria\n\n* Hospitalization within the past 3 months\n* Currently receiving oxygen therapy\n* Congestive heart failure (CHF) with an ejection fraction less than 25%\n* Severe aortic stenosis\n* Uncontrolled paroxysmal vertigo\n* Active neoplastic disease or terminal illness\n* Severe cognitive impairment\n* Neurological disorders (e.g., Parkinson's disease, multiple sclerosis)\n* Bedridden status\n* Major disability or mobility disorder\n* Chest pain at rest, during activities, or with physical exertion\n* History of loss of consciousness within the past 12 months\n* Medical advice to avoid vigorous physical activity","75 Years",{"count":209,"type":22},[25],"This study aims to examine the effects of a multi-component intervention incorporating Swiss ball exercises and nutritional counseling on reducing frailty in a sample of pre-frail older adults in primary care. It also aims to assess its effects on physical performance, functional status, and cognitive and well-being measures.\n\nParticipants aged between 65 and 75 years will be randomly assigned to the intervention group and \"usual care\" group .\n\nOver a 3-month period, the multi-component intervention will consist of Swiss ball exercises and nutritional counseling, whereas the \"usual care\" group will get verbal general health counseling on healthy eating and physical activity recommendations.\n\nOutcome Assessors who are blinded to treatment allocation will evaluate primary and secondary outcomes at the end of the intervention (3 months), and after 6 months follow-up period.",[237],"Frailty","2025-06-18",{"date":240,"type":33},"2025-06-24",{"date":242,"type":22},"2025-07",{"date":244,"type":22},"2027-07",{"name":39,"class":40},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":49,"sex":99,"minAge":253,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":41},"100593631","self-efficacy-and-knowledge-seek-trial-to-improve-sexual-reproductive-health-and-well-being-for-syrian-refugee-women-and-girls-in-lebanon-100593631","NCT07008950","Self-efficacy and Knowledge (SEEK) Trial to Improve Sexual Reproductive Health and Well-being for Syrian Refugee Women and Girls in Lebanon","SEEK","Inclusion Criteria:\n\n\\-\n\nThe target population of the study are Syrian adolescent girls and young women refugees (age 15-24 years) residing in Beqaa governorate in Lebanon. Participants will be included in the study if they meet the following inclusion criteria:\n\n1. are currently married and between the ages of 15 - 24 years,\n2. completed an average stay in Lebanon for a minimum of 6 months,\n3. are willing to take part in the study as indicated by them signing an informed consent (for young women 18 years of age or older) or through a legal guardian consent form and written assent for adolescents' girls between 15 and 17,\n4. have none of the exclusion criteria listed below upon screening.\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if they meet any of the following criteria:\n\n1. are currently pregnant and\u002For lactating,\n2. have reported chronic health problems interfering with the ability to follow the intervention protocol,\n3. have high levels of anxiety and\u002For depression as well as suicidal ideations and\u002For attempts upon screening and\u002For a current diagnosis of a severe mental illness, or undergoing mental health treatment.\n\n   \\-","15 Years",{"count":255,"type":22},485,[25],"This community-based randomized controlled trial (RCT) aims to evaluate a low-resource\u002Flow-intensity integrated sexual reproductive health (SRH) and wellbeing intervention package. It will be delivered in Primary Healthcare Centres (PHCs) in a rural area in Lebanon to Syrian refugee women and girls aged 15-24.",[259,260,261],"Mental Health Care","Sexual Health Quality of Life","Family Planning Services",[263,264,265,266,267,268,269,270],"sexual health","reproductive health","psychosocial support","wellbeing","RCT","Lebanon","Refugees","Girls and young women","2025-06-05",{"date":273,"type":33},"2025-06-06",{"date":275,"type":33},"2024-01-01",{"date":277,"type":22},"2025-06-30",{"name":39,"class":40},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":41},"100585532","phase-2-non-steroidal-anti-inflammatory-drugs-in-the-prevention-of-bone-pain-flares-after-palliative-radiotherapy-100585532","NCT06903585","Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy","Non-steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or older\n* Primary Solid tumor (Any type of solid tumor)\n* Painful bone metastases which are otherwise uncomplicated (no fracture and no neurologic symptoms due to nerve impingement or compression)\n* Baseline pain score on a numeric rating scale (0-10) of at least 2\n* Stable dose and schedule of narcotic medications prescribed\n\nExclusion Criteria:\n\n* Hematologic malignancy\n* Previously irradiated bone\n* Current use of steroids\n* Current use of NSAIDs which cannot be stopped before randomization\n* Contraindications for NSAIDs (hypersensitivity, PUD, prior GI bleed, CKD, HTN, HF, AERD\u002Fasthma)\n* Contraindications for PPIs",{"count":287,"type":22},385,[132],"Solid tumors have the tendency to spread to other organs in around 26% of cases, with many cases involving the bone causing severe bone destruction and pain that reduces patients' quality of life. Palliative radiation therapy is used as a standard of care to decrease cancer-related bone pain, as it has been proven to provide pain relief in many patients, either partially or totally, within only a few weeks. However, some patients experience worsening of bone pain especially within the first 10 days after radiation therapy, this is called bone pain flare, and its incidence is estimated to be around 40%. This pain flare tends to further reduce these patients' quality of life considering their main illness, which necessitates its prevention or alleviation.\n\nNon-Steroidal Anti-inflammatory Drugs (NSAIDs) which are a key component of the World Health Organization (WHO) analgesic options used to alleviate cancer pain have not had a good share of published trials in the prevention of bone pain flares.\n\nIn this light the investigators aim to conduct a double-blinded, placebo-controlled randomized controlled trial to investigate the effectiveness of NSAIDs, specifically Proxen, in preventing bone pain flares after palliative radiotherapy, and as a secondary endpoint they will compare the quality of life and side effects experienced by patients in either group.",[291,292],"Bone Pain Flare","Bone Metastasis","2025-04-01",{"date":295,"type":33},"2025-04-04",{"date":297,"type":22},"2025-04",{"date":299,"type":22},"2029-04",{"name":39,"class":40},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":49,"sex":17,"minAge":308,"maxAge":19,"enrollmentInfo":309,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":41},"100575868","comt-and-oprm1-polymorphisms-and-their-effect-on-post-operative-pain-in-children-100575868","NCT06777875","COMT and OPRM1 Polymorphisms and Their Effect on Post-Operative Pain in Children","COMT and OPRM1 Polymorphisms and Their Effect on Post-Operative Pain in Children Undergoing Orthopedic, Abdominal, Thoracic, and Plastic Surgeries.","Inclusion Criteria:\n\n* All children 8 years to 18 years\n* Undergoing orthopedic, abdominal, thoracic, and plastic surgeries\n* American Society of Anesthesiologists classification (ASA) I-II-III\n\nExclusion Criteria:\n\n* Children with schizoid personality disorders, phobias, and anxiety\n* Patients with neuropathic pain associated with surgeries requiring surgical treatment.\n* Children presented with all types of depressive disorders, atypical bipolar disorder, or a suspicion of substance abuse.\n* American Society of Anesthesiologists classification (ASA) ≥IV\n* All patients receiving regional anesthesia, local blocks, epidural and caudal blocks.","8 Years",{"count":310,"type":22},200,"OBSERVATIONAL","The goal of this observational study is to investigate whether the A118G single-nucleotide polymorphism (SNP) in the mu-opioid receptor1(OPRM1) and Catechol-O-methyltransferase (COMT) SNPs influence postoperative pain scores in children between the ages of 8 and 18 undergoing orthopedic, abdominal, thoracic, and plastic surgeries.\n\nThe main question\\[s\\] it aims to answer \\[is\\]:\n\nDo OPRM1 and COMT SNPs influence postoperative pain scores in children between the ages of 8 and 18 undergoing orthopedic, abdominal, thoracic, and plastic surgeries?\n\nParticipants will be assessed for their pain scores, sedation level, the amount of postoperative analgesics received, duration of their stay in the post-anesthesia care unit, and toxicity.",[314,315,316],"Pain","Genetic Change","Children, Only","2025-03-14",{"date":319,"type":33},"2025-03-18",{"date":321,"type":33},"2025-03-10",{"date":323,"type":22},"2027-01-13",{"name":39,"class":40},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":41},"100263285","phase-2-intravitreal-adalimumab-versus-subcutaneous-adalimumab-in-non-infectious-uveitis-100263285","NCT02706704","Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis","Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis","IVAS","Inclusion Criteria:\n\n* Subject is ≥ 18 years of age.\n* Subject is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis.\n* Subject must have active disease at baseline as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of prednisone ≥ 10 mg\u002Fday (or oral corticosteroid equivalent):\n\n  * Active, inflammatory, chorioretinal and\u002For inflammatory retinal vascular lesion\n  * ≥ 1+ anterior chamber cells (Standardization of Uveitis Nomenclature \\[SUN\\] criteria)\n  * ≥ 1+ vitreous haze (National Eye Institute \\[NEI\\]\u002FSUN criteria)\n* Subject with documented prior adequate response to oral corticosteroids (equivalent of oral prednisone up to 1 mg\u002Fkg\u002Fday).\n* If subject is on prednisone \\>=10 mg (or corticosteroid equivalent) at baseline, the dose has not been increased or decreased in the past 14 days.\n* No increase in the immune modulatory therapy in the past three months\n* Negative PPD test.\n* Positive PPD test on anti Tb medications.\n\nExclusion Criteria:\n\n* Subject with isolated anterior uveitis.\n* Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus, lyme disease, toxoplasmosis and herpes simplex virus (HSV).\n* Subject with serpiginous choroidopathy.\n* Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n* Subject with corneal or lens opacities that preclude the evaluation of the vitreous haze.\n* Subject with uncontrolled high intraocular pressure of ≥ 25 mmHg on maximal therapy.\n* Subject with intermediate uveitis and symptoms and\u002For MRI findings suggestive of a demyelinating disease such as multiple sclerosis. All subjects with intermediate uveitis must have had a prior brain MRI at time of or after diagnosis of intermediate uveitis.\n* Subject has received glucocorticosteroids implant (Retisert®), or Ozurdex within 6 months prior to baseline visit.\n* Subject has received intraocular or periocular corticosteroids or intravitreal methotrexate within 90 days prior to Baseline visit.\n* Subject with proliferative or severe non-proliferative diabetic retinopathy.\n* Subject with neovascular\u002Fwet age-related macular degeneration\n* Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process.\n* Subject with a systemic inflammatory disease and requires additional therapy with a systemic immunosuppressive agent at the time of study entry.\n* Subjects with history of active or latent Mycobacterium tuberculosis documented by Purified Protein Derivative (PPD) and chest X-ray and not anti tuberculosis (TB) treatment.",{"count":334,"type":22},32,[132],"The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg\u002F 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.",[338,339],"Uveitis","Non-Infectious Uveitis",[341,342],"Intravitreal Adalimumab","Subcutaneous Adalimumab","2025-02-24",{"date":345,"type":33},"2025-02-26",{"date":347,"type":33},"2016-02",{"date":349,"type":22},"2026-02",{"name":39,"class":40},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":49,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":368,"leadSponsor":370,"locationsCount":41},"100578796","enhancing-difficult-laryngoscopy-prediction-through-a-mixed-scoring-system-100578796","NCT06815952","Enhancing Difficult Laryngoscopy Prediction Through A Mixed Scoring System","Enhancing Difficult Laryngoscopy Prediction: A Prospective Study on A Mixed Scoring System With Ultrasound and Traditional Metrics","Inclusion Criteria:\n\n* Adult patients undergoing general anesthesia\n* American Society of Anesthesiologists (ASA) classification 1-4\n* Emergency or elective cases\n\nExclusion Criteria:\n\n* Patients with confirmed history of difficult airway\n* Patients with maxillofacial trauma or cervical spine injury or instability\n* Pregnant patients\n* Patients with a history of head and neck cancer\n* Patients with known subglottic stenosis\n* Patients requiring a double lumen tube insertion\n* Patients with a history of neck radiotherapy",{"count":359,"type":22},1100,"This study aims to develop a comprehensive airway assessment score including traditional bedside clinical tests and ultrasound measurements with high accuracy in predicting difficult airway, and to validate it through testing it on a large population sample. The main question it aims to answer is: Is the comprehensive scoring system that includes clinical bedside and ultrasound measurements developed to predict difficult airways valid in a large population sample? Adult patients undergoing general anesthesia with American Society of Anesthesiologists (ASA) classification 1-4 will be recruited. Traditional and ultrasound measurements will be collected.",[362,363,215],"Intubation","Laryngoscopy","2025-02-20",{"date":366,"type":33},"2025-02-21",{"date":364,"type":33},{"date":369,"type":22},"2026-02-01",{"name":39,"class":40},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":41},"100568834","phase-2-tetra-modality-bladder-preservation-strategies-in-muscle-invasive-bladder-cancer-turbt-chemoimmunotherapy-radiation-therapy-maintenance-immunotherapy-vs-ww-100568834","NCT06686381","Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo\u002FImmunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W","A Phase II, Randomized, Non-comparative Double Arm, Open-label, 2-stage, Multicenter Study to Evaluate the Efficacy and Safety of 2 Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer With Maximum TURBT Followed by Induction Platinum-based Chemotherapy\u002FAvelumab Followed by Radiation Therapy Then Maintenance Avelumab or Watch and Wait Approach","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form (ICF) before any trial related procedures.\n2. Male or female participant with ≥ 18 years of age at time of consenting.\n3. Participant is able and willing to comply with the requirements of trial protocol.\n4. Pathologically (histologically or cytologically) and radiologically confirmed newly diagnosed MIBC (T2-T4 N0 M0) or recurrent previously NMIBC.\n5. Histologically confirmed transitional cell carcinoma.\n6. Participant with ECOG Performance Status (PS) ≤ 1 at screening visit.\n7. An estimated life expectancy of more than 6 months.\n8. At screening visit, Left Ventricular Ejection Fraction LVEF \\>50% by echocardiography, for participants planned to receive DDMVAC.\n9. Participant must have adequate laboratory values at screening visit as follow:\n\n   1. Hematologic:\n\n      * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL\n      * Platelet count ≥ 100 × 10\\^9\u002FL\n      * Hemoglobin ≥ 9 g\u002FdL (may have been transfused)\n   2. Hepatic:\n\n      * Total bilirubin level ≤ 1.5 × ULN\n      * AST ≤ 2.5 × ULN\n      * ALT ≤ 2.5 × ULN\n   3. Renal:\n\n      * Estimated creatinine clearance \\> 50 mL\u002Fmin according to the Cockcroft-Gault formula\n      * Serum urea ≤ 1.5 x ULN\n      * Serum creatinine ≤ 1.5 x ULN.\n10. Female participant of childbearing potential must have a negative serum pregnancy test at screening.\n11. For female participant of childbearing potential: use one of the following highly effective contraception methods throughout the trial and for 30 days after the last Avelumab treatment administration.\n\n    * combined (estrogen and progesterone) hormonal contraception associated with inhibition of ovulation: either oral, intravaginal or transdermal\n    * progesterone-only hormonal contraception associated with inhibition of ovulation: either oral, injectable or implantable\n    * intrauterine device (IUD)\n    * intrauterine hormone-releasing system (IUS)\n    * bilateral tubal occlusion\n    * vasectomised partner (provided that partner is the sole sexual partner of the female trial participant and that the vasectomised partner has received medical assessment of the surgical success)\n    * sexual abstinence\n\nExclusion Criteria:\n\n1. Participant with non-muscle invasive bladder cancer or Metastatic disease (M1) and\u002For lymph node positive.\n2. Participant who underwent radical cystectomy or is planned for radical cystectomy.\n3. Histologically confirmed squamous cell carcinoma, micropapillary carcinoma, neuroendocrine carcinoma, adenocarcinoma, or mixed histology.\n4. Participant had received treatment for urothelial carcinoma, with any of the following anti-cancer therapies prior the first dose of trial treatment: systemic chemotherapy, targeted small molecule therapy, or radiation therapy.\n5. Participant had received prior treatment with any drug or antibody (anti-PD-1, anti-PD- L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody) targeting T-cell co-stimulation or checkpoint pathways.\n6. Participant who are not eligible to receive DDMVAC or Cisplatin-Gemzar.\n7. History of severe hypersensitivity to Avelumab or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI- CTCAE v5.0 Grade ≥ 3).\n8. Participant with hydronephrosis.\n9. Active infection requiring systemic therapy within 28 days before the first dose of trial treatment (e.g., urinary tract infection).\n10. History of testing positive for the human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.\n11. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening visit (positive Hepatitis B surface antigen (HBsAg) or HCV RNA if anti-HCV antibody screening test is positive).\n12. Participant currently using immunosuppressive medication, except for the following:\n\n    * Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).\n    * Systemic corticosteroids at physiologic doses ≤ 10 mg\u002Fday of prednisone or equivalent.\n    * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n13. Active autoimmune diseases that might deteriorate upon receiving an immune- stimulatory agent. Conditions such as vitiligo, psoriasis, diabetes type I, or hypo - or hyper-thyroid diseases not requiring immunosuppressive treatment are eligible.\n14. Participant has any of the following medical conditions: Addison's disease, thyroiditis\u002FHashimoto's thyroiditis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture's syndrome, and Grave's disease.\n15. Any psychiatric condition that would prohibit the understanding or rendering of informed consent form.\n16. Hepatic insufficiency manifesting as clinical jaundice, hepatic encephalopathy, and\u002For variceal bleed within 60 days prior to screening.\n17. Clinically significant, active cardiovascular disease, such as:\n\n    * Transmural myocardial infarction within 6 months of enrollment\n    * Unstable angina\n    * Congestive heart failure (New York Heart Association Classification Grade II or greater)\n    * Serious cardiac arrhythmia requiring medical treatment\n18. Cerebral vascular accident\u002F stroke within 6 months of enrollment.\n19. End-stage renal disease requiring dialysis.\n20. Participant has severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior.\n21. Prior organ transplantation including allogenic stem-cell transplantation.\n22. Treatment with an investigational agent within 28 days before the first dose of trial treatment.\n23. Participation in another clinical trial.\n24. Participants who are taking prohibited medication.\n25. Pregnant or breastfeeding women or who are planned to get pregnant or breastfeed during the trial.\n26. Vaccination within 4 weeks of the first dose of Avelumab is prohibited except for administration of inactivated vaccines.\n27. Persisting toxicity related to prior therapy with Grade \\> 1 (NCI-CTCAE v 5.0); with the exception of: alopecia, sensory neuropathy Grade ≤ 2, or other toxicity with Grade ≤ 2 not constituting a safety risk based on investigator's judgment.",{"count":209,"type":22},[132],"The purpose of this study is to assess the efficacy and safety of adding the immunotherapy Avelumab as a fourth component, alongside tumor removal, chemotherapy, and radiation, to increase the chance of preserving the bladder in the treatment of muscle-invasive bladder cancer.",[382],"Muscle-invasive Bladder Cancer",[384,385,386,387],"Muscle-invasive bladder cancer","Bladder preservation","Avelumab","Tetramodalities","2025-02-03",{"date":390,"type":33},"2025-02-05",{"date":392,"type":22},"2025-04-15",{"date":394,"type":22},"2028-08-15",{"name":39,"class":40},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":420,"locationsCount":41},"100374251","phase-2-comparative-evaluation-of-mebo-ointment-and-topical-diltiazem-ointment-in-the-treatment-of-acute-anal-fissure-100374251","NCT04153032","Comparative Evaluation of MEBO Ointment and Topical Diltiazem Ointment in the Treatment of Acute Anal Fissure","Comparative Evaluation of MEBO Ointment and Topical Diltiazem Ointment in the Treatment of Acute Anal Fissure: a Randomized Clinical Trial","MEBO","Inclusion Criteria:\n\n* Subjects must be 18 years and above.\n\n  * Subjects with 3 months (90 days) or less history of painful anal fissure (AF), prior to screening, where AF-related pain-associated with, or following, defecation is experienced at least twice a week during the symptomatic phase, with pain scores at an average of ≥ 3 on an 11-point NRS (Numerical Rating Scale, range 0-10 where 0 = no pain and 10 = worst pain imaginable).\n  * Subjects with an average of ≥4 on an 11-point NRS during the screening phase for worst anal pain associated with, or following, defecation for the most recent 3 days on which the subject has defecated.\n  * Subjects with evidence of a radial fissure, with induration at the edges, seen on anal examination.\n  * Willing to stop all other concomitant topical preparations applied perianally prior to commencing study treatment, and throughout the study. There will be a \"washout\" period of at least 2 weeks prior to commencing the study for subjects who were using other concomitant topical preparations applied perianally.\n  * Able to give consent\n\nExclusion Criteria:\n\n* Subjects unwilling to be examined for AF.\n* Subjects who have undergone the following procedures:\n\n  * Lateral sphincterotomy or anal stretch or other previous surgery involving the anal canal or perianal region (hemorrhoidectomy, anal fistula surgery).\n  * Incision of perianal abcess.\n* Subjects who have had sub-fissure injection of botulinum toxin within 6 months period prior to screening, or have used glyceryl trinitrate (GTN) ointment for \\>1 week in the 4 weeks prior to the screening visit.\n* Subjects with AF associated with other conditions (drug-induced \\[e.g. nicorandil\\], trauma, HIV infection, fistula-in-ano, inflammatory bowel disease, perianal sepsis or malignancy).\n* Subjects with cardiovascular disease\n* Subjects with known hypersensitivity to DTZ or the ingredients of MEBO (Sesame oil)\n* Subjects taking medications prohibited by the protocol.\n* Subjects who have taken experimental agents must have been discontinued at least 8 weeks prior to screening, or for a period equivalent to 5 half-lives (t1\u002F2) of the agents.\n* Subjects who have the following gastrointestinal disorders:\n\n  * Inflammatory bowel disease.\n  * Chronic faecal incontinence.\n  * History of radiation therapy to the pelvis.\n  * Fixed anal stenosis\u002Ffibrosis.\n* Subjects with major psychiatric (including drug or alcohol abusers), or haematological illness. (diseases of the vascular system; source: )Subjects with planned elective or other treatment requiring hospitalization, during the study, booked before entry into the study.\n* Subjects who will be unavailable for the duration of the trial, likely to be noncompliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason.\n* Patients who are taking oral therapy for anal fissure will also be excluded from the study.",{"count":405,"type":22},183,[132],"No study to date has compared topical DTZ to MEBO ointment in the treatment of anal fissure. Therefore, the present study aims to compare the efficacy and safety of DTZ to MEBO in the treatment of acute anal fissure. The investigators propose to conduct a comparative randomized clinical study. In this study, the investigators will compare patients with acute anal fissure receiving MEBO ointment vs Topical DTZ ointment vs a combination of MEBO and DTZ ointment.\n\nHypothesis:\n\nMEBO in combination with DTZ is more effective than DTZ or MEBO alone in the treatment of acute anal fissure.",[409],"Anal Fissure",[411,402,412,413],"Anal fissure","topical diltiazem","MEBO\u002FDiltiazem combination","2025-01-28",{"date":416,"type":33},"2025-01-29",{"date":418,"type":33},"2019-12-01",{"date":143,"type":22},{"name":39,"class":40},{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":41},"100326238","comparing-wound-complications-after-elective-abdominal-surgery-using-two-closure-techniques-100326238","NCT03527433","Comparing Wound Complications After Elective Abdominal Surgery Using Two Closure Techniques","A Randomized, Controlled Trial Comparing Wound COmplications in Elective Midline Laparotomies After FAscia Closure Using Two Different Techniques of Running Sutures: COFACTOR-trial","COFACTOR","Inclusion Criteria:\n\n* Age 18 years or older\n* Signed Informed Consent\n* Undergoing an elective laparotomy through a midline incision\n* Undergoing a midline laparoscopic procedure (midline laparoscopic extraction site)\n\nExclusion Criteria:\n\n* Emergency surgery\n* Laparotomy through an incision other than midline\n* Previous midline laparotomy\n* Presence of incisional or ventral hernia at time of laparotomy\n* Incisional hernia repair\n* Laparotomy surgery during pregnancy",{"count":430,"type":22},274,[25],"Wound complications, increased hospital stays and post-operative morbidity are all common following abdominal surgery. Abdominal closure complications are strongly associated with the closure technique and material used. The traditional closure technique used by surgeons is placing the wide and large stitches. A randomized controlled trial done in Sweden described a new closure technique in surgeries by placing the stitches closer to each other by using narrow. The results showed lower incidence of wound infections, hernias, and wound rupture. However, the study provides low quality evidence on the benefits of this new technique since it has numerous limitations like lack of standardization of suture size, lack of proper randomization, and heterogeneity in patient eligibility which will increase result bias. There is still a need for quality evidence on the effectiveness of this new closing technique procedure at decreasing wound complications after the operation.\n\nIn this trial the investigators will compare two techniques in the closure of abdominal wounds in patients undergoing abdominal surgery. The first technique will be the traditional closure technique currently used in abdominal surgery. The second technique will be using the new closure technique. The closure of abdominal wounds with small and close sutures using the new technique is expected to lower the incidence of hernia and wound complications as well as improve the quality of life of the patient. Potential candidates for the study are those who will be undergoing elective midline laparotomy at AUBMC. The patients and assessor of outcomes will be blinded and patients will be randomized to receive either the traditional or new closure operation technique. There are no anticipated risks for those participating in the study. All data and information collected will be kept confidential.\n\nHypothesis:\n\nClosure of abdominal fascia in elective midline laparotomy incisions with small and close sutures compared to closure with conventional wide and distant sutures results in lower rates of wound rupture, incisional hernia, and wound infection, and improved quality of life.\n\nSignificance:\n\nThe results of this study will allow surgeons to assess the role of a new abdominal closure technique in decreasing short and long term postoperative complications, for a commonly performed procedure. This trial will generate evidence-based conclusions.",[434],"Wound Complication",[436,437,438],"Incisional hernia","Wound infection","Midline laparotomy",{"date":416,"type":33},{"date":441,"type":33},"2019-10-01",{"date":443,"type":22},"2025-12",{"name":39,"class":40},{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":49,"sex":17,"minAge":19,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":41},"100438495","the-effect-of-different-diets-on-arterial-stiffness-in-obese-patients-on-semaglutide-100438495","NCT04990024","The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide","The Effect of Mediterranean or High Protein\u002FLow Carbohydrate Diet on Arterial Stiffness in Non-diabetic, Obese Patients on Semaglutide: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Men and premenopausal women, 18-49 years, with obesity defined as BMI ≥ 30 kg\u002Fm2\n* Upon the initiation of Semaglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician\n* Able to commit for a 6-month trial visits\n\nExclusion Criteria:\n\n* Pregnant women\n* Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months\n* Patients who have undergone metabolic weight loss surgery\n* Patients known to have diabetes (HbA1c ≥6.5% at screening)\n* Patients with uncontrolled hypertension\n* Patients with uncontrolled cardiac disease, pulmonary, renal or liver diseases, active cancer or psychiatric diseases\n* Patients with excessive alcohol intake, defined as ≥ 2 glasses per day\n* Patients known to have uncontrolled\u002F untreated thyroid disorders.\n* Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and\u002For cessation of the culprit medication to lose weight\n* Patients with untreated gout\n* Patients who have undergone bariatric surgery","49 Years",{"count":454,"type":22},60,[25],"In patients initiating Semaglutide for weight management, the objective is to compare the effect of the Mediterranean diet and the high protein\u002Flow carbohydrate (HP\u002FLC) diet CV parameters, namely arterial stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), and visceral adipose tissue, in addition to other metabolic indicators.",[458,459],"Obesity","Weight Loss","2024-08-03",{"date":462,"type":33},"2024-08-06",{"date":464,"type":33},"2021-07-01",{"date":466,"type":22},"2025-09-15",{"name":39,"class":40},{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":475,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":483,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":41},"100495272","ultrasound-guided-microendoscopic-versus-fluoroscopic-guided-lumbar-transforaminal-epidural-steroid-injections-100495272","NCT05729022","Ultrasound-Guided Microendoscopic Versus Fluoroscopic-Guided Lumbar Transforaminal Epidural Steroid Injections","Ultrasound-Guided Microendoscopic Versus Fluoroscopic-Guided Lumbar Transforaminal Epidural Steroid Injections: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 64 years old of either sex\n* Disease status of American Society of Anesthesiologists grades I to II\n* Patients presenting with single-level disc disease and radiculopathy (L2-L3; L3-L4; L4-L5) for steroid injection\n* Confirmation of herniated disk by CT or MRI\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Age under 18 or over 64 years old\n* Pregnant women\n* Disease status of American Society of Anesthesiologists grades III to IV\n* Unable to provide an informed consent\n* Radiculopathies at multiple spinal levels\n* Non-lumbar herniated discs\n* Clinically obvious or known spinal deformity or stenosis\n* Previous spine surgery\n* Local or systemic infection\n* Allergy to steroids, anesthetics, or contrast material\n* Uncorrectable coagulopathy and patients on anticoagulation therapy\n* Patients who refuse the procedure\n* Spine tuberculosis or tumors\n* Prior injections within 3 months","64 Years",{"count":477,"type":22},124,[25],"The purpose of this study is to compare the Microendoscopic combined with ultrasound technique to the standard routinely used X-ray guided transforaminal steroid injection technique.",[481,482],"Radiculopathy Lumbar","Disc Disease Lumbar",[484,485,486,487],"Epidural Injections","Lumbar Manipulation","Fluoroscopy","Ultrasound","2024-06-19",{"date":490,"type":33},"2024-06-21",{"date":492,"type":22},"2024-12-01",{"date":494,"type":22},"2025-12-01",{"name":39,"class":40},{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":17,"minAge":504,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":507,"conditions":508,"keywords":513,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":41},"100125506","lebanese-interhospital-pneumococcal-surveillance-program-100125506","NCT00901602","Lebanese Interhospital Pneumococcal Surveillance Program","Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)","LIPSP","Inclusion Criteria:\n\n* Samples included in the study are those that are:\n\n  * culture proven\n  * invasive pneumococcal infections\n  * in patients of all ages admitted to different hospitals all over Lebanon\n* Acceptable samples include:\n\n  * positive isolates from blood\n  * cerebrospinal fluid\n  * other normally sterile body sites such as empyema fluid, abscesses, joint fluid, middle ear fluid obtained by tympanocentesis in the operating room, and lung needle aspiration\n\nExclusion Criteria:\n\n* non S. pneumoniae isolates","1 Day",{"count":506,"type":22},700,"Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.",[509,510,511,512],"Pneumonia","Meningitis","Sepsis","Bacteremia",[514,515,516,517,518,519,520],"streptococcus pneumoniae","pneumococcus","pneumonia","meningitis","serotypes","bacteremia","sepsis","2023-02-02",{"date":523,"type":33},"2023-02-03",{"date":525,"type":4},"2005-10",{"date":527,"type":22},"2030-10",{"name":39,"class":40},""]